Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[18F]PR04.MZ is a fluorine-18 labeled tropane derivative used as a positron emission tomography (PET) radiotracer for imaging the dopamine transporter (DAT). It is characterized by high affinity and selectivity for DAT, providing a more accurate assessment of presynaptic dopaminergic neuron density compared to earlier tracers. Clinical research has focused on its utility in the differential diagnosis of Parkinson's disease (PD) and atypical parkinsonian syndromes, such as progressive supranuclear palsy (PSP) and multiple system atrophy (MSA), particularly within the first five years of symptom onset. Notably, it is capable of visualizing dopaminergic loss in the substantia nigra pars compacta (SNpc), a feature that distinguishes it from many other DAT ligands.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on [18F]PR04.MZ.